blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1501830

EP1501830 - 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES [Right-click to bookmark this link]
Former [2005/05]7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES
[2007/46]
StatusNo opposition filed within time limit
Status updated on  10.08.2012
Database last updated on 14.11.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
Actelion Pharmaceuticals Ltd.
Gewerbestrasse 16
4123 Allschwil / CH
[2005/05]
Inventor(s)01 / BEZENCON, Olivier
Äussere Baslerstrasse 137
CH-4125 Riehen / CH
02 / BUR, Daniel
Im Rosengarten 24
CH-4106 Therwil / CH
03 / FISCHLI, Walter
Obertorweg 64
CH-4123 Allschwil / CH
04 / REMEN, Lubos
Kurzelängeweg 28
CH-4123 Allschwil / CH
05 / RICHARD-BILDSTEIN, Sylvia
12 rue des Beaux prés
F-68440 Dietwiller / FR
06 / WEBER, Hans-Peter
Seewenweg 45
CH-4146 Hochwald / CH
07 / WELLER, Thomas
Hoelzlistrasse 58
CH-4102 Binningen / CH
 [2005/18]
Former [2005/12]01 / BEZENCON, Olivier
Äussere Baslerstrasse 137
CH-4125 Riehen / CH
02 / BUR, Daniel
Im Rosengarten 24
CH-4106 Therwil / CH
03 / FISCHLI, Walter
Obertorweg 64
CH-4123 Allschwil / CH
04 / REMEN, Lubos
Kurzelängeweg 28
CH-4123 Allschwil / CH
05 / RICHARD-BILDSTEIN, Sylvia
34a, rue D'ottmarsheim
F-68170 Rixheim / FR
06 / WEBER, Hans-Peter
Seewenweg 45
CH-4146 Hochwald / CH
07 / WELLER, Thomas
Hoelzlistrasse 58
CH-4102 Binningen / CH
Former [2005/05]01 / BEZENCON, Olivier
Dürrenmattweg 53
CH-4123 Allschwil / CH
02 / BUR, Daniel
Im Rosengarten 24
CH-4106 Therwil / CH
03 / FISCHLI, Walter
Obertorweg 64
CH-4123 Allschwil / CH
04 / REMEN, Lubos
Kurzelängeweg 28
CH-4123 Allschwil / CH
05 / RICHARD-BILDSTEIN, Sylvia
34a, rue D'ottmarsheim
F-68170 Rixheim / FR
06 / WEBER, Hans-Peter
Seewenweg 45
CH-4146 Hochwald / CH
07 / WELLER, Thomas
Hoelzlistrasse 58
CH-4102 Binningen / CH
Representative(s)Schager, Frank
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil / CH
[N/P]
Former [2011/40]Schager, Frank
Actelion Pharmaceuticals Ltd Gewerbestrasse 16
4123 Allschwil / CH
Former [2005/05]Schager, Frank, Dr.
Actelion Pharmaceuticals Ltd Gewerbestrasse 16
4123 Allschwil / CH
Application number, filing date03727287.908.04.2003
[2005/05]
WO2003EP03721
Priority number, dateWO2002EP0470529.04.2002         Original published format: PCT/EP02/04705
[2005/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03093267
Date:13.11.2003
Language:EN
[2003/46]
Type: A1 Application with search report 
No.:EP1501830
Date:02.02.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 13.11.2003 takes the place of the publication of the European patent application.
[2005/05]
Type: B1 Patent specification 
No.:EP1501830
Date:05.10.2011
Language:EN
[2011/40]
Search report(s)International search report - published on:EP13.11.2003
ClassificationIPC:C07D471/08, A61K31/4995
[2005/05]
CPC:
C07D471/08 (EP,KR,US); C07D487/08 (KR); A61K31/4995 (EP,KR,US);
A61K45/06 (EP,US); A61P13/12 (EP); A61P15/10 (EP);
A61P27/06 (EP); A61P3/10 (EP); A61P37/02 (EP);
A61P9/00 (EP); A61P9/10 (EP); A61P9/12 (EP);
Y02A50/30 (EP,US) (-)
C-Set:
A61K31/4995, A61K2300/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/05]
Extension statesLT29.11.2004
LV29.11.2004
TitleGerman:7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-EN-DERIVATE UND IHRE VERWENDUNG ALS RENIN-INHIBITOREN ZUR BEHANDLUNG VON BLUTHOCHDRUCK, HERZ-KREISLAUF-ERKRANKUNGEN UND NIERENKRANKHEITEN[2010/28]
English:7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES[2010/28]
French:DERIVES DE 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION, DE MALADIES CARDIOVASCULAIRES OU RENALES[2010/28]
Former [2005/05]7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-EN-DERIVATE UND IHRE VERWENDUNG ALS RENIN-INHIBITOREN ZUR BEHANDLUNG VON BLUTHOCHDRUCK, HERZ-KREISLAUF-ERKRANKUNGEN UND NIERENKRANKHEITEN
Former [2005/05]7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES
Former [2005/05]DERIVES DE 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION, DE MALADIES CARDIOVASCULAIRES OU RENALES
Entry into regional phase29.11.2004National basic fee paid 
29.11.2004Designation fee(s) paid 
29.11.2004Examination fee paid 
Examination procedure09.09.2003Request for preliminary examination filed
International Preliminary Examining Authority: EP
29.11.2004Examination requested  [2005/05]
26.01.2005Despatch of a communication from the examining division (Time limit: M06)
04.08.2005Reply to a communication from the examining division
09.09.2005Despatch of a communication from the examining division (Time limit: M06)
13.01.2006Reply to a communication from the examining division
04.11.2009Despatch of a communication from the examining division (Time limit: M06)
21.04.2010Reply to a communication from the examining division
20.08.2010Communication of intention to grant the patent
30.12.2010Fee for grant paid
30.12.2010Fee for publishing/printing paid
07.02.2011Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.01.2005
Opposition(s)06.07.2012No opposition filed within time limit [2012/37]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
29.03.2011Request for further processing filed
29.03.2011Full payment received (date of receipt of payment)
Request granted
09.05.2011Decision despatched
Fees paidRenewal fee
02.05.2005Renewal fee patent year 03
02.05.2006Renewal fee patent year 04
02.05.2007Renewal fee patent year 05
02.05.2008Renewal fee patent year 06
04.05.2009Renewal fee patent year 07
03.05.2010Renewal fee patent year 08
02.05.2011Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.04.2003
AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
TR05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
GB08.04.2012
IE08.04.2012
IT08.04.2012
LU08.04.2012
ES09.04.2012
CH30.04.2012
FR30.04.2012
LI30.04.2012
MC30.04.2012
[2014/34]
Former [2014/27]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
TR05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
GB08.04.2012
IE08.04.2012
IT08.04.2012
LU08.04.2012
ES09.04.2012
CH30.04.2012
FR30.04.2012
LI30.04.2012
MC30.04.2012
Former [2014/21]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
TR05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
GB08.04.2012
IE08.04.2012
IT08.04.2012
ES09.04.2012
CH30.04.2012
FR30.04.2012
LI30.04.2012
MC30.04.2012
Former [2013/36]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
GB08.04.2012
IE08.04.2012
IT08.04.2012
ES09.04.2012
CH30.04.2012
FR30.04.2012
LI30.04.2012
MC30.04.2012
Former [2013/29]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
FI05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
GB08.04.2012
IE08.04.2012
IT08.04.2012
CH30.04.2012
FR30.04.2012
LI30.04.2012
MC30.04.2012
Former [2013/13]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
GB08.04.2012
IE08.04.2012
IT08.04.2012
CH30.04.2012
FR30.04.2012
LI30.04.2012
MC30.04.2012
Former [2013/11]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
GB08.04.2012
IE08.04.2012
IT08.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
Former [2013/10]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
GB08.04.2012
IE08.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
Former [2013/08]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
IE08.04.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
Former [2013/07]AT05.10.2011
BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
CH30.04.2012
LI30.04.2012
MC30.04.2012
Former [2012/50]BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
MC30.04.2012
Former [2012/36]BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
NL05.10.2011
RO05.10.2011
SE05.10.2011
SI05.10.2011
SK05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
Former [2012/35]BE05.10.2011
CY05.10.2011
CZ05.10.2011
DK05.10.2011
EE05.10.2011
NL05.10.2011
SE05.10.2011
SI05.10.2011
BG05.01.2012
GR06.01.2012
PT06.02.2012
Former [2012/34]BE05.10.2011
CY05.10.2011
CZ05.10.2011
NL05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/28]BE05.10.2011
CY05.10.2011
NL05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/24]BE05.10.2011
NL05.10.2011
SE05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/23]BE05.10.2011
NL05.10.2011
SI05.10.2011
GR06.01.2012
PT06.02.2012
Former [2012/21]BE05.10.2011
SI05.10.2011
Former [2012/11]SI05.10.2011
Cited inInternational search[A]US3509161  (DOLD OTTO, et al) [A] 1-12 * Formula (I); examples 1-9; Table in col. 8 *;
 [AD]WO9709311  (HOFFMANN LA ROCHE [CH]) [AD] 1-12 * Claims; Formula (I); examples 82-85, 86(eee), 147 *;
 [A]  - S.A. EL-ABBADY, "ENHANCED REACTIVITY OF PYRIDIN-3-OL TOWARDS 4-PHENYL-1,2,4-TRIAZOLINE-3,5-DIONE: FMO TREATMENT OF THE CYCLOADDITION PROCESS BY ASED-MO CALCULATIONS METHOD", ZAGAZIG J. PHARM. SCI., (1996), vol. 5, no. 1, pages 68 - 74, XP001154254 [A] 1-12 * Compounds (4) and (5) *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.